Table of Contents
Volume 2012, Article ID 104707, 9 pages
Research Article

Aspirin Prophylaxis for the Prevention of Thrombosis: Expectations and Limitations

1Lillehei Heart Institute, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
2Departments of Pathology and Pharmacology, Loyola University Medical Center, 2160 South First Avenue, Maywood, IL 60153, USA

Received 16 June 2011; Accepted 31 October 2011

Academic Editor: Christian Doutremepuich

Copyright © 2012 Gundu H. R. Rao and Jawad Fareed. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Platelets play a very important role in the pathogenesis of acute vascular events leading to thrombosis of the coronary and cerebral arteries. Blockage of these arteries leading to regional ischemia of heart and brain tissues precipitate heart attacks and stroke. Acetyl salicylic acid (Aspirin) has been the drug of choice for over half a century for the primary and secondary prophylaxis of thrombotic events. In spite of its extensive use as an antiplatelet drug for the prevention of vascular thrombosis, there is considerable concern about the degree of protection it offers, to patients under aspirin therapy. In this paper, we explain the phenomenon of aspirin resistance, discuss the limitations of aspirin therapy, and suggest methods to monitor “at-risk” individuals. Ability to monitor and determine at risk patients will provide opportunities for the clinicians to customize antiplatelet therapies.